Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 163.77% | -387.01% | |||
| Gross Profit | -163.77% | 387.01% | |||
| SG&A Expenses | 24.68% | 11.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.33% | 28.18% | |||
| Operating Income | -31.33% | -28.18% | |||
| Income Before Tax | -34.37% | -24.87% | |||
| Income Tax Expenses | -43.10% | 205.26% | |||
| Earnings from Continuing Operations | -33.75% | -25.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.75% | -25.46% | |||
| EBIT | -31.33% | -28.18% | |||
| EBITDA | -31.32% | -28.24% | |||
| EPS Basic | -12.22% | -13.13% | |||
| Normalized Basic EPS | -12.70% | -12.62% | |||
| EPS Diluted | -12.22% | -13.13% | |||
| Normalized Diluted EPS | -12.70% | -12.62% | |||
| Average Basic Shares Outstanding | 19.20% | 10.91% | |||
| Average Diluted Shares Outstanding | 19.20% | 10.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||